Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TSHA Taysha Gene Therapies Inc
- Stocks
- Healthcare
- NASDAQ: TSHA
Price (delayed)
$2.1
Market cap
$430.5M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.36
Enterprise value
$350.17M
Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, Taysha aims to rapidly translate our treatments from bench to
Highlights
Taysha Gene Therapies's quick ratio has increased by 35% YoY
Taysha Gene Therapies's net income has increased by 20% YoY
Taysha Gene Therapies's EPS has shrunk by 157% QoQ but it has surged by 63% YoY
Taysha Gene Therapies's revenue has decreased by 46% YoY and by 16% QoQ
The gross profit has decreased by 46% YoY and by 16% QoQ
Key stats
What are the main financial stats of TSHA
Market
Valuations
Earnings
Shares outstanding
205M
Market cap
$430.5M
Enterprise value
$350.17M
Price to earnings (P/E)
N/A
Price to book (P/B)
6.02
Price to sales (P/S)
63.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
42.02
Revenue
$8.33M
Gross profit
$8.33M
Operating income
-$91.46M
Net income
-$89.3M
EBIT
-$89.2M
EBITDA
-$86.73M
Free cash flow
-$81.6M
Per share
Balance sheet
Liquidity
EPS
-$0.36
EPS diluted
-$0.36
Free cash flow per share
-$0.33
Book value per share
$0.35
Revenue per share
$0.03
TBVPS
$0.64
Total assets
$160.36M
Total liabilities
$88.84M
Debt
$61.3M
Equity
$71.53M
Working capital
$115.9M
Debt to equity
0.86
Current ratio
5.42
Quick ratio
5.4
Net debt/EBITDA
0.93
Margins
Efficiency
Dividend
EBITDA margin
-1,040.8%
Gross margin
100%
Net margin
-1,071.6%
Operating margin
-1,097.6%
Return on assets
-51.5%
Return on equity
-110.6%
Return on invested capital
-179.5%
Return on capital employed
-66.5%
Return on sales
-1,070.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TSHA stock price
How has the Taysha Gene Therapies stock price performed over time
Intraday
10.53%
1 week
-12.86%
1 month
85.84%
1 year
-11.76%
YTD
21.39%
QTD
51.08%
Financial performance
How have Taysha Gene Therapies's revenue and profit performed over time
Revenue
$8.33M
Gross profit
$8.33M
Operating income
-$91.46M
Net income
-$89.3M
Gross margin
100%
Net margin
-1,071.6%
TSHA's operating margin has shrunk by 134% YoY and by 24% QoQ
The net margin has contracted by 48% YoY
Taysha Gene Therapies's revenue has decreased by 46% YoY and by 16% QoQ
The gross profit has decreased by 46% YoY and by 16% QoQ
Price vs fundamentals
How does TSHA's price correlate with its fundamentals
Growth
What is Taysha Gene Therapies's growth rate over time
Valuation
What is Taysha Gene Therapies stock price valuation
P/E
N/A
P/B
6.02
P/S
63.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
42.02
Taysha Gene Therapies's EPS has shrunk by 157% QoQ but it has surged by 63% YoY
The company's equity fell by 19% QoQ and by 4.6% YoY
TSHA's price to book (P/B) is 2% higher than its last 4 quarters average of 5.9
Taysha Gene Therapies's revenue has decreased by 46% YoY and by 16% QoQ
TSHA's price to sales (P/S) is 30% more than its last 4 quarters average of 48.4
Efficiency
How efficient is Taysha Gene Therapies business performance
The return on invested capital has surged by 85% year-on-year
Taysha Gene Therapies's return on sales has shrunk by 55% YoY
Taysha Gene Therapies's return on assets has increased by 36% YoY
Dividends
What is TSHA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TSHA.
Financial health
How did Taysha Gene Therapies financials performed over time
The company's total assets is 81% higher than its total liabilities
Taysha Gene Therapies's quick ratio has increased by 35% YoY
The current ratio is up by 33% year-on-year
The debt is 14% less than the equity
Taysha Gene Therapies's debt to equity has increased by 26% QoQ and by 9% YoY
The company's equity fell by 19% QoQ and by 4.6% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.